BridgeMD
New treatment option for Alcohol Use Disorder
Official title Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
ClinicalTrials.gov ID: NCT05855668
What this study is testing
- What it's testing
- This 2-arm study will recruit participants with 1) alcohol use disorder and 2) cannabis use disorder for a 12-week cognitive behavioral therapy, following a thorough baseline assessments on executive function, incentive salience, and negative emotionality.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient has been referred to or intends to participate in either the AUD or CUD Integrated Care Pathway (and is therefore willing to participate in...
- Able to communicate and provide informed consent in English.
- 18 years of age or older.
- Willing and able to safely abstain from substances (other than nicotine or tobacco products), including alcohol and cannabis, for 12 hours prior to...
- Meets DSM-5 diagnostic criteria for AUD (AUD group) or CUD (CUD group)
You likely can't join if
- Active suicidal ideation at time of assessment.
- Suicide attempt within the past month.
- Unstable psychiatric or medical status (e.g., acute psychosis or mania) or unstable use of another substance that may interfere with participation in...
- Enrollment in another study that conflicts with the procedures or scientific integrity of this study.
- Individuals planning to be out of the province for a substantial amount of time during the treatment period will not be permitted to enroll.
See the full eligibility criteria
- Patient has been referred to or intends to participate in either the AUD or CUD Integrated Care Pathway (and is therefore willing to participate in group psychotherapy).
- Able to communicate and provide informed consent in English.
- 18 years of age or older.
- Willing and able to safely abstain from substances (other than nicotine or tobacco products), including alcohol and cannabis, for 12 hours prior to the eligibility and task-based assessments.
- Meets DSM-5 diagnostic criteria for AUD (AUD group) or CUD (CUD group)
- Meets criteria for risky drinking, defined as \> 10 drinks per week for females and \> 15 drinks per week for males on average over the past 30 days (AUD group) or daily or near-daily cannabis use over the past 30 days...
- Active suicidal ideation at time of assessment.
- Suicide attempt within the past month.
- Unstable psychiatric or medical status (e.g., acute psychosis or mania) or unstable use of another substance that may interfere with participation in groups (e.g. active fentanyl use).
- Enrollment in another study that conflicts with the procedures or scientific integrity of this study.
- Individuals planning to be out of the province for a substantial amount of time during the treatment period will not be permitted to enroll.
The study team makes the final eligibility decision.
Where it's taking place
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.